Influence of Intensive Lipid-lowering on FFRCT (The FLOW-PROMOTE Study)

Inclusion Criteria: 1. Symptoms suggestive of stable coronary artery disease (CAD) 2. No known CAD 3. At least one coronary stenosis with \>49% lumen reduction determined by CT angiography 4. Sinus rhythm 5. At least one lesion with FFRCT \<0.81 (see below) 6. Life expectancy \>3 years 7. Fertile women must use safe contraception throughout the study period 8. Signed informed consent 5\. LDL cholesterol \>2.0 mM (patients already on lipid lowering medical therapy \< 3 months can be included if meeting all of the above mentioned criteria) Exclusion Criteria: 1. Unstable angina 2. Known CAD 3. Body mass index \>40 4. Allergy to iodinated contrast media 5. Known statin intolerance 6. Poor coronary CT angiography image quality inadequate for FFRCT calculation (determined by core-laboratory) 7. Significant left main coronary artery (stenosis \>49%) or three-vessel CAD determined by coronary CT angiography leading to direct referral to ICA 8. FFRCT \<0.81 over the left main coronary artery or the proximal left anterior descendens artery (LAD) segment, or \<0.76 over the mid-LAD, proximal circumflex, right coronary artery or intermediate coronary segments 9. Pregnancy (women with age \>45 will be screened for pregnancy) 10. Moderate to severe liver failure 11. Estimated glomerular filtration rate (eGFR) \< 60 ml/min 12. Participation in another trial 13. Does noes not wish to participate